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Metastatic renal cell carcinoma (RCC) to the contralateral ureter is a rare phenomenon. We report a
metastatic RCC to the contralateral ureter 5months after right radical nephrectomy for Fuhrman grade 3/4
clear cell adenocarcinoma with pathologic T3 staging. The distal ureter was excised followed by partial
ileal ureteral substitution. Pathology conﬁrmed metastatic clear cell RCC Fuhrman grade 2/4. Ileal ureteral
substitution has been shown to provide good long-term functional outcomes and should be considered as
a possible option for surgical treatment of ureteral metastasis.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
After nephrectomy for localized renal cell carcinoma (RCC) be-
tween 20% 40% of patients will develop metastatic or locally
recurring disease.1 RCCwithmetastasis to the contralateral ureter is
a rare phenomenon of which to our knowledge only 7 cases have
been described. We report a case involving the management of a
patient who presented with metachronous RCC metastasis to the
contralateral ureter.Case report
An asymptomatic 61-year-old male presented with left hydro-
nephrosis extending from the renal pelvis to the S2 level on sur-
veillance CT imaging. His past medical history was notable for right
radical nephrectomy in August 2014 for right renal cell carcinoma,
with metastasis to the lungs and mediastinum, and chronic kidney
disease. Pathology revealed Fuhrman grade 3/4 clear cell adeno-
carcinoma with pathologic T3N1M0 staging. Following uneventful
radical nephrectomy, the patient was started on 800 mg PO daily
Pazopanib. Follow-up surveillance CT imaging showed regression of: þ1 206 744 3294.
Inc. This is an open access article uhis mediastinal and retroperitoneal lymphadenopathy; however,
CT imaging performed 5 months after his nephrectomy revealed an
enhancing mass in his left distal ureter.
As a result of the surveillance CT imaging ﬁndings, ﬂexible
ureteroscopy and ureteral cytology of the left ureter was per-
formed; however cytology ﬁndings were not conclusive for a
diagnosis. A left ureteral stent was placed that was later transi-
tioned to a nephrostomy tube in preparation of open reconstructive
surgery. The metastatic work-up included CT urogram, serum
chemistries, and cystoscopy.
CT urogram demonstrated a mid-to-distal 2.2 cm obstructing
intraluminal mass of the ureter with no contrast distal to the mass.
Serum creatinine was 1.4 mg/dL, GFR 51, hemoglobin 14.6 g/dL.
Calcium and phosphate were within normal limits, and urinalysis
and urine culture were negative. Cystoscopy was performed to
assess for bladder volume, as a Boari ﬂap was considered for ure-
teral reconstruction. The results revealed that the patient’s bladder
capacity was approximately 200 mL, and he was not considered an
appropriate candidate for a Boari ﬂap. After discussion the patient
was consented to open distal ureterectomy with ileal ureter crea-
tion. An upper midline incision was made, the left ureter was
identiﬁed and dissected, and the mass was palpated at the mid-
portion of the ureter. Five-centimeters of the mid-portion of left
ureter was excised to obtain negative tumor-margins. Twelve-
centimeters of ileum was placed from the bladder to the uppernder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Microscopic image (100) of the left ureter lined by normal urothelium
(black arrow) and facing metastatic tumor nodule (white arrow) ﬁlling ureteral lumen.
The tumor is composed of clear cells with classic architecture of alveolar nests and
tightly packed tubules surrounded by delicate blood vessels. An immunohistochem-
istry with a sensitive and speciﬁc marker of renal tubular origin PAX8 showed diffuse
nuclear staining of tumor and conﬁrming morphologic impression of extra-renal
metastasis of clear cell RCC, Fuhrman grade 2.
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distally. An 8 French  24 cm double pigtail ureteral stent, 20
French Foley catheter, and JP drain were placed. Pathologic evalu-
ation of the 3.5 cm mass conﬁrmed metastatic clear cell RCC
Fuhrman grade 2/4 (Fig. 1). Final permanent surgical margins were
free of carcinoma. The patient had no complications following
surgery and will be followed with cystoscopy in clinic. He has
resumed his Pazopanib, at the recommendation of his oncologist
and follow-up CT 7/15/2015 showed no lymphadenopathy.
Discussion
Shoemaker ﬁrst described ileal ureteral substitution in 1906, but
it was not until 1959 that this method of reconstruction became
popular.2 Since that time ileal ureter replacement has become the
preferred method of ﬁxing long ureteral defects, or as in our case,
ureteral defects that are not amenable to other reconstructive
techniques.
Verduyckt et al3 followed 18 patients who underwent ileal
ureteral substitution between 1981 and 2000. Of these patients 86%
had good renal function 65-months post-operatively. The authors
reported that six patients required several surgical re-interventions
in the long-term for obstruction at the uretero-ileal anastomosis,
recurrent hematuria, stenosis, and uretero-ileal calculi. Six patients
developed recurrent urinary tract infections (UTI), of which only
one patient was treated uneventfully with antibiotic therapy.
A retrospective study reviewed 17 patients who underwent ileal
ureteral substitution from 1980 to 2010 of which 11 patients had
improved or stable renal function, while 3 patients required dial-
ysis.4 Recurrent UTI developed in 5 patients, of which 2 patients
developed chronic pyelonephritis requiring surgical management.More recently, some researchers have started to evaluate the
beneﬁts of open vs. minimally invasive approach to performing ileal
ureter substitution. Sim et al2 retrospectively reviewed a total of 5
patients who underwent minimally invasive ileal ureter substitu-
tion. Four of the patients were treated laparoscopically and 1 pa-
tient was treated robotically. At 22-month median follow-up there
were no noted complications.
In 2009 Stein et al, reported on 14 patients who had undergone
laparoscopic or open ileal ureter substitution. They noted that pa-
tients who underwent laparoscopy recuperated faster andwere less
likely to require narcotic analgesics compared to their open ileal
ureter counterparts. The authors also reported that 3 patients
presented with post-operative complications of pneumonia, urine
leak, and ureteral injury after transection of the ureter during
laparoscopy.
Currently, there have been 51 reported cases of metastatic RCC
to the ureter; with only 9 reported cases to the contralateral ure-
ter5,6 that we are aware of. Reconstructive options for metachro-
nous metastasis to the contralateral ureter should be determined
based on the length of the defect, bladder capacity, and location of
the defect. As in our case, ileal ureteral substitution proved a suit-
able option for the surgical management of our patient’s metastatic
clear cell adenocarcinoma. Recent studies suggest potential beneﬁts
with use of minimally invasive ileal ureter substitution. However,
more data is needed comparing these minimally invasive tech-
niques to an open approach. Long-term outcome studies have re-
ported overall good functional kidney outcomes following
substitution of ureter for ileum.
Conclusion
Patients with ureteral metastasis often develop loss of renal
function, which is critical in a solitary unit. Although the ureter is a
rare site for metachronus metastases to occur, excision and recon-
struction should be considered to reduce disease burden, preserve
renal function, and maintain quality of life. Ileal ureter substitution
provides good long-term outcomes and should be considered for
patients diagnosed with ureteral metastasis.
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